Information Provided By:
Fly News Breaks for February 28, 2018
ARCT
Feb 28, 2018 | 07:39 EDT
Ladenburg Thalmann analyst Wangzhi Li downgraded Arcturus Therapeutics to Neutral from Buy without a price target. The analyst believes "significant uncertainty" has been created by recent management changes and organizational disputes. Unplanned departures of core inventors of the company's Lunar platform create "significant risks and uncertainty," Li tells investors in a research note. The analyst recommends investors remain on the sidelines pending greater clarity.
News For ARCT From the Last 2 Days
There are no results for your query ARCT